Back to results
US 12,741,009 B2Granted
Oral liposomal compositions
OwnerJean-Yves Renaultinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to a liposomal composition administered orally, nasally or pulmonary comprising a negatively charged phospholipid, optionally a zwitterionic phospholipid, a sterol, and one or more substance (s) amphiphilic (s) of biological interest, preferably a lipophilic immunostimulant useful for treating and/or preventing any pathology implementing the activation of monocytes and/or macrophages.
Claims5
An oral liposomal composition for oral administration, the composition comprising:
- a) from 0.1 to 10% by weight of muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) relative to the weight of the liposomal composition;
- and
- b) a liposome comprising:
- i) from 25% to 35% by weight of di-oleoyl-phosphatidylserine (DOPS) relative to the total weight of the liposome,
- ii) from 30% to 50% by weight of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine (DPPC), di-myristoyl-phosphatidyl-choline (DMPC), or di-linoleoyl-phosphatidyl-choline (DLPC), relative to the total weight of the liposome, and
- iii) from 20% to 30% by weight of cholesterol, relative to the total weight of the liposome, wherein the liposomal composition is stable in the presence of bile salts.
3 more elements
Dependencies are inferred from the claim text.